IP Library › Granted Patent US 12,195,758
Granted Patent B2
US 12,195,758 · App. 17/495,411 · Granted Jan 14, 2025

Xeno-free generation of tissue-specific progenitor cells

Inventors: Peiman Hematti (Middleton, WI); Jaehyup Kim (Madison, WI)
Assignee: Wisconsin Alumni Research Foundation
C12N5/0647A61K35/28C12N5/0676C12N5/0693C12N5/0694G01N33/5073A61K2035/124C12N2502/1157C12N2502/1358C12N2506/02C12N2506/22
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,195,758
App. No.
17/495,411
Granted
Jan 14, 2025
Kind
B2
Abstract

The invention relates to purified, tissue-specific progenitors, methods of making and using such tissue-specific progenitors.

Claims (18)

1. An in vitro population of tissue-specific progenitor cells produced by a method comprising co-culturing a CD14+ cell, a tissue-specific mesenchymal stem cell (MSC), and a pluripotent cell in vitro until the pluripotent cell differentiates into a cell exhibiting a phenotype characteristic of a progenitor of a cell of a tissue of interest and isolating the progenitor cell.

2. The population of tissue-specific progenitor cells of claim 1 , wherein the CD14+ cell is a monocyte.

3. The population of tissue-specific progenitor cells of claim 1 , wherein the CD14+ cell is a macrophage.

4. The population of tissue-specific progenitor cells of claim 3 , wherein the macrophage is generated by a method comprising culturing a peripheral blood monocyte until it becomes the macrophage.

5. The population of tissue-specific progenitor cells of claim 1 , wherein the CD14+ cell is obtained by culturing under xeno-free conditions a peripheral blood monocyte until the peripheral blood monocyte exhibits a phenotype characteristic of a CD14+ monocyte-derived macrophage.

6. The population of tissue-specific cells of claim 1 , wherein the tissue of interest is selected from the group consisting of bone marrow, pancreas, heart, adipose, lung, liver, skin, kidney, and thyroid.

7. The population of tissue-specific progenitor cells of claim 1 , wherein the tissue-specific progenitor is selected from the group consisting of a hematopoietic progenitor, a cardiomyocyte progenitor, and a pancreatic islet progenitor.

8. The population of tissue-specific progenitor cells of claim 1 , wherein the pluripotent cell is a human embryonic stem cell or a human induced pluripotent cell.

9. The population of tissue-specific progenitors of claim 1 , wherein the CD14+ cell, the MSC, and the pluripotent cell are syngeneic with regard to each other.

10. The population of tissue-specific progenitors of claim 1 , wherein the CD14+ cell, the MSC, and the pluripotent cell are allogenic with regard to each other.

11. The population of tissue-specific progenitors of claim 1 , wherein the CD14+ cell, the MSC, and the pluripotent cell are autologous with regard to each other.

12. The population of tissue-specific progenitors of claim 1 , wherein the tissue-specific progenitor cells express CD26.

13. The population of tissue-specific progenitors of claim 1 , wherein the tissue-specific progenitor cells are enriched.

14. The population of tissue-specific progenitors of claim 1 , wherein the MSC is obtained from bone marrow, pancreas, heart, adipose, lung, liver, skin, kidney, or thyroid tissue.

15. The population of tissue-specific progenitors of claim 1 , wherein the MSC is produced from a pluripotent cell.

16. The population of tissue-specific progenitor cells of claim 1 , wherein the method further comprises isolating the tissue-specific progenitor cells.

17. The population of tissue-specific progenitor cells of claim 1 , wherein the tissue-specific progenitor cells are capable of engraftment.

18. A cell culture composition comprising the in vitro population of tissue-specific progenitor cells of claim 1 , wherein the population of tissue-specific progenitor cells is enriched.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2021
From: KIM, JAEHYUP; HEMATTI, PEIMAN
To: WISCONSIN ALUMNI RESEARCH FOUNDATION
Reel/Frame 057749/0852 →
Continuity (5)
Division 16004633 · Jun 11, 2018
Division 15154653 · May 13, 2016
Continuation 13231753 · Sep 13, 2011
Provisional Application 61382095 · Sep 13, 2010
Related Publication 20220127577A1 · Apr 28, 2022
References Cited (36)
US 20080213230A1 · Phillips · 2008 [cited by examiner]
Weissman, Irving J; “Stem and Progenitor Cells: Origins, Phenotypes, Lineage Commitments, and Transdifferentiations” Annual Review of Cell and Developmental Biology, 17, 387-403, 2001 (Year: 2001). [cited by examiner]
Prabhash, K; et al; “CD26 expression in donor stem cell harvest and its correlation with engraftment in human haematopoietic stem cell transplantation: potential predictor of early engraftment” Annals of Oncology, 21, 5… [cited by examiner]
Bessis et al., “Iron metabolism in the bone marrow as seen by electron microscopy: a critical review.” Blood 19:635-663 (1962). [cited by applicant]
Chasis et al., “Erythroblastic islands: niches for erythropoiesis.” Blood. 112:470-478 (2008). [cited by applicant]
Cheng et al., “Human adult marrow cells support prolonged expansion of human embryonic stem cells in culture.” Stem Cells 21:131 (2003). [cited by applicant]
Dominici et al., “Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.” Cytotherapy 8(4):315 (2006). [cited by applicant]
Dorrell, “Isolation of major pancreatic cell types and long-term culture-initiating cells using novel human surface markers.” Stem Cell Res. 1(3):183-194 (2008). [cited by applicant]
Eisenberg, et al. “Stem Cell Plasticity, Cell Fusion, and Transdifferentiation” Birth Defects Research, 69, 209-218, 2003. [cited by applicant]
Gordon, “The macrophage: past, present and future.” Eur J Immunol. Nov. 2007; 37 Suppl 1:S9-17. [cited by applicant]
Hideshima et al., “Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets.” Nat. Rev. Cancer 7:585-598 (2007). [cited by applicant]
Honda, et al., “In-vitro enhancement of mouse embryonic development by co-culture with peritonel macrophages” Human Reproduction, 9, 692-696, 1994. [cited by applicant]
Jaiswal et al., “CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis.” Cell 138:271 (2009). [cited by applicant]
Kaufman et al., “Hematopoietic colony-forming cells derived from human embryonic stem cells” PNAS 98(19):10716 (2001). [cited by applicant]
Khazen, et al. “Expression of macrophage-selective markers in human and rodent adipocytes” Federation of European Biochemical Societies, 579, 5631-5634, 2005. [cited by applicant]
Ludwig et al. “Feeder-independent culture of human embryonic stem cells.” Nat. Methods 3(8):637-646 (2006). [cited by applicant]
Nakano et al., “Generation of lymphohematopoietic cells from embryonic stem cells in culture” Science 265(5175):1098 (1994). [cited by applicant]
Narayan et al., “Human embryonic stem cell-derived hematopoietic cells are capable of engrafting primary as well as secondary fetal sheep recipients.” Blood 107:2180 (2005). [cited by applicant]
Parenteau “Commercial development of cell-based therapeutics: strategic considerations along the drug to tissue spectrum” Regenerative Medicine, vol. 4, No. 4, pp. 601-611 (2009). [cited by applicant]
Pollard, “Trophic macrophages in development and disease.” Nature Rev. 9:259-270 (2009). [cited by applicant]
Simon et al., “The role of oxygen availability in embryonic development and stem cell function.” Nat. Rev. Mol. Cell Biol. 9(4):285 (2008). [cited by applicant]
Stella et al., “CD34-Positive Cells: Biology and Clinical Relevance” Haematologica 80(4):367 (1995). [cited by applicant]
Stout et al., “Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences” J. Immunol. 175:342-349 (2005). [cited by applicant]
Tarnok et al., “Phenotypes of stem cells from diverse origin.” Cytometry 77(1):6-10 (2010). [cited by applicant]
Trivedi, et al. “Derivation and immunological characterization of mesenchymal stromal cells from human embryonic stem cells” Exp. Hematol. 36(3):350-359 (2008). [cited by applicant]
Trivedi, et al., “Simultaneous generation of CD34+ primitive hematopoietic cells and CD73+ mesenchymal stem cells from human embryonic stem cells cocultured with murine OP9 stromal cells” Experimental Hematology, 35, 14… [cited by applicant]
Urbaniak Hunter et al., “Gene- and cell-based approaches for neurodegenerative disease.” Adv. Exp. Med. Biol. 671:117-130 (2010). [cited by applicant]
Vodyanik et al., “Human embryonic stem cell-derived CD34+ cells: efficient production in the coculture with OP9 stromal cells and analysis of lymphohematopoietic potential” Blood 105(2):617(2005). [cited by applicant]
Yang et al., “CD3(+) and/or CD14(+) depletion from cord blood mononuclear cells before ex vivo expansion culture Improves total nucleated cell and CD34(+) cell yields.” Bone Marrow Transplant. 45(6):1000 (2010). [cited by applicant]
Zheng et al., “Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis” Blood 114(17):3625-8 (Oct. 2009). [cited by applicant]
Kim et al., “Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages” Exp Hematol. 37(12):1445-1453 (2009). [cited by applicant]
Doetschman et al., “The in vitro development of blastocyst-derived embryonic stem cell lines: formation of visceral yolk sac, blood islands and myocardium” J. Embryol. Exp. Morphol. 87, 27-45 (1985). [cited by applicant]
Zheng et al., “Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis” Blood, 114: 3625-3628 (2009). [cited by applicant]
Schoppmann, et al., “Tumor-Associated Macrophages Express Lymphatic Endothelial Growth Factors and are Related to Peritumoral Lymphangiogenesis” American Journal of Pathology, 161(3):947-956 (2002). [cited by applicant]
Kukreja et al., “Enhancement of clonogenicity of human multiple myeloma by dendritic cells” The Journal of Experimental Medicine, 203(8):1859-1865 (2006). [cited by applicant]
Wang et al., “Survivin is upregulated in myeloma cell lines cocultured with mesenchymal stem cells” Leukemia Research, 34(10):1325-1329 (Oct. 2010). [cited by applicant]